首页>投融资
BetterLife Pharma
IPO后其他轮次
BetterLife Pharma Inc formerly (Pivot Pharmaceuticals Inc) (previously Neurokine Pharmaceuticals Inc) is focused on the development and commercialization of therapeutic pharmaceuticals and nutraceuticals, and also drug delivery platform technologies.In December 2020, BetterLife Pharma Inc had signed a definitive agreement to acquire 100% of the assets in Transcend Biodynamics LLC valued at $10 million in an all-stock transaction for a total of 13,333,333 common shares at $0.75 per share. Later that month, BetterLife Pharma Inc. announced that company has completed its acquisition to acquire 100% of the assets in Transcend Biodynamics LLC in an all-stock transaction..In June 2020, the company announced that had entered into an exclusivity definitive agreement with Altum Pharmaceuticals, pursuant to which BetterLife would issue 4.582 common shares of BetterLife for each Altum common share, which represented approximately $36.1 million in value based on the proposed share exchange as at M
基本信息
-
公司全称BetterLife Pharma Inc
-
类型精神和神经疾病治疗药品研发、制造商
-
产业领域药品研发/制造、生物药
-
公司人数不明确
-
地址1275 West 6th Avenue VANCOUVER BRITISH COLUMBIA V6H 1A6; CA; Telephone: +14388848841; Fax: +16045515178;
-
联系电话604-221-0595
-
邮箱ir@neurokine.com
-
成立时间2002-06-10
投融资
-
2023-12-18IPO后其他轮次20万美元未透露
-
2023-03-14IPO后其他轮次185.71万美元未透露
-
2017-12-22上市未透露未透露
相关投融资企业
D轮
AgomAb是一种开创性的治疗方法,可以调节再生途径来实现组织结构修复和功能器官恢复。我们不断增长的高特异性单克隆抗体管道,旨在治疗一系列急性和慢性疾病,包括炎症、代谢和纤维化过程。通过将新的科学见解与强大的发展专业知识相结合,我们正在建立一家公司,引导真正再生药物的出现。
股权融资
上海药明海德生物科技有限公司是由海利生物(股票代码:603718.SH)与药明生物(WuXi Biologics, 2269.HK)共同成立的合资企业,并提供人用疫苗从概念到商业化生产全过程的发现、开发及生产“端到端”服务及解决方案平台,主要从事人用疫苗(包括癌症疫苗)合同定制研发生产(CDMO)业务,致力于打造全球疫苗行业领先的一体化能力和技术平台。